Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why STAAR Surgical Company Shares Are Seeing Big Gains

By Sean Williams - Mar 17, 2014 at 2:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

STAAR Surgical surges after a positive FDA panel review. Can shares head even higher?

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of STAAR Surgical ( STAA -2.95% ), a developer of implantable lenses for the eye that treat astigmatism and myopia, surged as much as 27% after receiving a positive view from the Food and Drug Administration's panel on its Visian Toric implantable collamer lens, or Visian TICL.

So what: According to STAAR Surgical's press release, the FDA's Ophthalmic Devices Panel of the Medical Devices Advisory Committee voted favorably on all three questions posed to it by the FDA's division of Ophthalmic, Neurological, and Ear, Nose and Throat Devices. The questions primarily revolved around the safety of Visian TICL and its benefits relative to its risks. As STAAR Surgical's release also noted, the Visian TICL would allow surgeons to correct astigmatism and myopia during a single procedure. Following this favorable news, research firm Canaccord Genuity boosted its rating on STAAR Surgical to buy from hold with a price target of $20, implying 30% upside to Friday's closing price.

Now what: This is good news for STAAR Surgical, which has done an efficient job of expanding its product pipeline and indications in what looks to be a rapidly growing ophthalmic market over the coming decades given the retirement of baby boomers. It's perhaps a bit concerning from a shareholder's perspective that STAAR has missed Wall Street's EPS estimates in the past three quarters, but given its double-digit revenue growth potential, it's a company I'd suggest adding to your watchlist and keeping an eye on (no pun intended), especially if it has any significant dips.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

STAAR Surgical Company Stock Quote
STAAR Surgical Company
$89.37 (-2.95%) $-2.72

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.